SEC Form 4 · accession 0001193125-26-256124
Xenon Pharmaceuticals Inc. · XENE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Justin D. Gover
Director
Period of report
Jun 1, 2026
Accepted (ET)
Jun 3, 2026 · 9:04 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001582313
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Jun 1, 2026 | M | 2,645 | — | A | 2,645 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF1 | — | Jun 1, 2026 | M | 2,645 | D | — | — | Common Shares | 2,645 | 0 | D |
| Share Option (Right to Buy)F2 | $53.46 | Jun 3, 2026 | A | 10,507 | A | — | Jun 2, 2036 | Common Shares | 10,507 | 10,507 | D |
| Restricted Share UnitsF3 | $0.00 | Jun 3, 2026 | A | 1,593 | A | — | — | Common Shares | 1,593 | 1,593 | D |
Explanation of responses
- F1Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.
- F2Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.
- F3Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.